These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8899499)

  • 1. Predictive factors of a response to interferon therapy in chronic hepatitis C.
    Nomura H; Kimura Y; Tada H; Hisano C; Morita C; Okamoto O; Shiraishi G; Kashiwagi S
    J Clin Gastroenterol; 1996 Oct; 23(3):185-90. PubMed ID: 8899499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus.
    Kumada T; Nakano S; Takeda I; Sugiyama K; Osada T; Kiriyama S; Toyoda H; Sasa T; Shibata M; Morishima T; Nakano I; Fukuda Y; Kosaka Y; Tameda Y; Nakashima M
    J Gastroenterol Hepatol; 1996 Feb; 11(2):159-65. PubMed ID: 8672762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices.
    Bjøro K; Krarup H; Bell H; Christophersen P; Evensen S; Frøland SS; Laursen A; B vd Lippe B; Maeland A; Ranek L
    Scand J Gastroenterol; 1995 Nov; 30(11):1119-24. PubMed ID: 8578174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
    Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.
    Shindo M; Arai K; Sokawa Y; Okuno T
    Ann Intern Med; 1995 Apr; 122(8):586-91. PubMed ID: 7887552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients.
    Fallows G; Kaita K; Minuk G; Penner F; Smart G; Dawood M; Rosser B
    Can J Gastroenterol; 2000; 14 Suppl B():30B-35B. PubMed ID: 10938502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
    Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
    Yuen MF; Lai CL
    Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.